Bandingkan dokter dan harga Terapi sel T CAR teratas di Israel. Temukan pencocokan terbaik Anda di sini.
Kami akan memilih dokter terbaik berdasarkan kebutuhan dan anggaran Anda.
Ditinjau secara medis oleh Fahad Mawlood
Editor Medis & Data ScientistDokter teratas
14
Israel
Ulasan
14000+
Dari pasien asli
Bandingkan harga untuk Terapi sel T CAR di negara-negara teratas
Ketuk negara untuk melihat dokter teratas dan harga
Dapatkan rencana perawatan yang dipersonalisasi gratis dan pilih opsi terbaik. Tanpa komitmen · Tidak ada pembayaran untuk layanan kami
Tampilkan pertama:
Dr. Ram Ron berspesialisasi dalam terapi sel T CAR di Pusat Medis Sourasky (Ichilov), membawa keahlian yang luas untuk pengobatan canggih ini.
Dr. Ron Ram telah melakukan beberapa ratus transplantasi sel punca (stem cell) dan menerbitkan lebih dari 30 artikel ilmiah di bidang hematologi dan onkologi.
Kepala Onkohematologi Anak di Rumah Sakit Anak Dana Dwek – Dr. Ronit El Hasid berspesialisasi dalam transplantasi sumsum tulang dan darah untuk anak-anak.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Michael Shapira berspesialisasi dalam Transplantasi Sumsum Tulang di Pusat Medis Sourasky (Ichilov), dengan pengalaman yang luas di bidang tersebut.
Direktur hematologi onkologi pediatrik di Pusat Medis Sourasky – berspesialisasi dalam terapi sel T CAR untuk anak-anak dengan kelainan darah dan sarkoma.
Dengan 31 tahun pengalaman, Dr. Aviv berspesialisasi dalam terapi sel T CAR di Pusat Medis Sourasky (Klinik Ichilov).
Dr. Yair telah memberikan kontribusi signifikan terhadap hematologi, khususnya dalam leukemia limfositik kronis, dengan sejumlah penghargaan dan penelitian yang telah diterbitkan.
Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.
She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.
Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.
Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.
She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.
Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.
Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.
He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.
He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).
Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.
He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.
He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.
Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.
He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.
Memilih klinik di luar negeri bisa membuat stres. Di Bookimed, dengan 800.000+ pasien telah dibantu, kami memahami kekhawatiran Anda. Kami tahu cara menemukan dokter terpercaya, opsi harga terbaik, dan solusi bahkan untuk kasus yang rumit. Kami siap membimbing Anda di setiap langkah.
Yan Matsiivskiy
Kepala Tim Koordinator Medis
4300++ perjalanan pasien yang dipandu
3 tahun di Bookimed
142 pasien dari Israel telah menemukan dokternya melalui kami bulan ini
Kuis 2 menit
Ceritakan tujuan, anggaran, dan waktu Anda
Pencocokan Manusia + AI
Algoritme kami menemukan kecocokan, koordinator memverifikasi kesesuaian
Pilihan Anda Siap
Bandingkan harga, paket, tanggal. Chat dengan koordinator Anda
Bingung dengan banyak pilihan?
Membimbing pengobatan Anda
Koordinator pribadi berpengalaman medis
| Peringkat | Dokter | pengalaman | Cocok Untuk | Apa yang Membedakan Mereka | Klinik & Lokasi | Konsultasi |
|---|---|---|---|---|---|---|
| #1 | 24 tahun pengalaman | Terapi sel T CAR | Berspesialisasi dalam terapi seluler lanjutan di pusat onkologi terkemuka, dengan fokus pada rencana perawatan yang dipersonalisasi. | Israel | Harga berdasarkan permintaan | |
| #2 | 24 tahun pengalaman | Keganasan hematologi | Memiliki pengalaman luas dalam transplantasi sel punca, disertai kontribusi akademik, termasuk lebih dari 30 artikel yang telah dipublikasikan. Telah menyelesaikan pelatihan fellowship di New York Medical College. | Israel | Harga berdasarkan permintaan | |
| #3 | 38 tahun pengalaman | Terapi sel T CAR Pediatrik | Memimpin departemen transplantasi pediatrik dengan 300+ transplantasi telah dilakukan. Telah menerbitkan 50+ makalah dan merupakan anggota asosiasi hematologi utama. | Israel | Harga berdasarkan permintaan | |
| #4 | 36 tahun pengalaman | Transplantasi Sumsum Tulang | Berspesialisasi dalam Transplantasi Sumsum Tulang dengan keahlian tingkat senior. Pelatihan dilaksanakan di Hadassah Medical Center yang bergengsi dan Hebrew University. | Israel | Harga berdasarkan permintaan | |
| #5 | 41 tahun pengalaman | Kelainan darah pediatrik dan sarkoma | Memimpin departemen hematologi onkologi anak Sourasky – dilatih di institut global terkemuka untuk kanker masa kanak-kanak. Mengkoordinasikan program perawatan sarkoma Israel. | Israel | Harga berdasarkan permintaan | |
| #6 | 34 tahun pengalaman | Terapi sel T CAR | Berspesialisasi dalam onkohematologi dengan pengalaman puluhan tahun dalam terapi seluler canggih. Bekerja di Pusat Medis Sourasky, institusi terkemuka di Israel. | Israel | Harga berdasarkan permintaan | |
| #7 | 24 tahun pengalaman | Leukemia limfositik kronis | Berspesialisasi dalam leukemia limfositik kronis, dengan berbagai penghargaan dan hibah penelitian. Anggota asosiasi hematologi terkemuka. | Israel | Harga berdasarkan permintaan |
You do not need a specific CAR T-cell referral to begin. Any hematologist or community oncologist can initiate the process to a specialized center. However, a multidisciplinary team at an accredited Israeli hospital must confirm your final eligibility for treatment.
Bookimed Expert Insight: While any hematologist can refer you, selecting a doctor with a high volume of related procedures speeds up valid documentation. For example, Dr. Ivetta Danylesko at Sheba Medical Center has performed over 3,000 procedures. Working with such experienced specialists helps ensure your medical history meets specific clinical trials or protocol requirements faster.
Patient Consensus: Patients note that pushing a local oncologist to refer directly to a CAR T-cell team can help bypass general queues. Many emphasize that having all previous treatment lines documented is vital for the multi-center board review. It is also common for patients to plan for a three to four month wait even after the initial referral.
Verify Israeli CAR T-cell therapy doctors by confirming their board certification in hematology and oncology through the Scientific Council of the Israel Medical Association. Leading specialists often hold international memberships in the American Society of Hematology and have completed fellowship training at top US institutions.
Bookimed Expert Insight: Data shows that premier Israeli specialists often hold significant leadership roles in global organizations. For instance, Dr. Arnon Nagler at Sheba Medical Center served as the Chair for the European Society for Blood and Marrow Transplantation (EBMT) committees. This level of international leadership indicates that these doctors don't just follow protocols but actually help create the global standards for CAR T-cell therapy and transplant medicine.
Patient Consensus: Patients mention that top-tier doctors are very open about sharing their personal results and response rates. They noticed that experienced specialists often have many co-author credits on major clinical trials. Families emphasize that the most skilled pediatric doctors have deep experience in handling complex cases at dedicated children's hospitals.
When choosing a CAR T-cell therapy doctor in Israel, you should look for board-certified hematologists and oncologists with specialized training in cellular immunotherapy. Leading experts often lead bone marrow transplant departments and have extensive experience in treating complex blood cancers like leukemia and lymphoma.
Bookimed Expert Insight: Data shows that premier Israeli specialists combine clinical leadership with heavy research involvement. For example, Prof. Arnon Nagler at Sheba Medical Center pioneered reduced-intensity transplant protocols. Choosing a doctor who also serves as a department director ensures they oversee the entire cell processing and recovery cycle at JCI-accredited facilities.
Patient Consensus: Patients often emphasize the importance of finding a doctor familiar with bridging therapies used before the actual cell infusion. They note that feeling supported by a team experienced in managing post-infusion side effects made their recovery much smoother. Many were relieved to work with specialists who have personal experience running clinical trials for the latest cellular products.
Major public medical centers in Israel like Sheba and Sourasky (Ichilov) staff board-certified hematologists with international fellowships in cellular immunotherapy. These facilities operate specialized units for CAR T-cell therapy. Experts here maintain credentials from the American Society of Hematology and other global bodies.
Bookimed Expert Insight: Data shows that Israeli public centers often feature surgeons who also lead specialized research departments. For example, Dr. Herishanu Yair at Sourasky heads the CLL Department while managing CAR T-cell protocols. This dual role means patients receive care from doctors who directly contribute to the latest clinical protocols and published research.
Patient Consensus: Patients note that doctors at these centers speak English at a level comparable to US specialists. They often mention the long 6-8 month waitlists for public slots but feel the advanced cellular facilities are worth the wait. Many are surprised by how quickly centers like Sheba can manufacture the cells on-site.
Private CAR T-cell therapy consultations with senior Israeli specialists typically range from $500 to $1,350. The public sector offers significantly lower costs for residents through health funds. However, private sessions provide immediate access to department heads and personalized treatment plans without the long wait times.
Bookimed Expert Insight: Data shows that senior specialists in Tel Aviv often maintain dual roles as department heads and private consultants. Dr. Fredi Aviv and Dr. Herishanu Yair bring over 25 years of experience to these sessions. Choosing a private consult at a center like Sourasky allows patients to bypass the standard 6-month public approval queue.
Patient Consensus: Patients note that while public sector co-pays are minimal, the bureaucracy can delay urgent care. Many choose private sessions to get a treatment plan started in days. They describe the experience as worth the cost for the direct time spent with a professor.
Patients should expect a high level of English proficiency from CAR T-cell therapy specialists in Israel. Most leading doctors hold American Board certifications or have completed fellowships at prestigious institutions like Stanford University and SUNY Brooklyn. Hospitals provide dedicated interpretation services for international patients to navigate complex treatment stages.
Bookimed Expert Insight: Data shows that senior hematologists in Israel often have dual training from both Israeli and North American institutions. For example, Dr. Arnon Nagler at Sheba Medical Center is a Stanford-trained pioneer, while Dr. Ronit El Hasid at Sourasky practiced at City of Hope in Los Angeles. This specific international background means they are comfortable using English as a primary language for medical discussions.
Patient Consensus: Patients find that while lead doctors speak excellent English, some nursing staff may have more limited language skills. Many suggest using a translation app for quick bedside needs but note that hospital coordinators are essential for understanding complex physician instructions.
Israel leads CAR T-cell innovation by running early-phase trials with homegrown constructs for blood cancers and solid tumors. Top experts like Dr. Ron Ram at Sourasky Medical Center (Ichilov) and specialists at Sheba Medical Center develop proprietary vectors. These programs often provide faster access than commercial therapies from the US.
Bookimed Expert Insight: A unique pattern in Israel is the integration of high-level international training within local research clinics. For example, Dr. Ron Ram and Dr. Arnon Nagler both completed fellowships at Stanford University, while Dr. Ronit El Hasid trained at City of Hope. This global expertise allows Israeli centers to successfully run dual US-Israel clinical trials for complex off-the-shelf and bispecific CAR-T products.
Patient Consensus: Patients note that Israeli doctors often provide access to logic-gated constructs after US programs decline their cases. Relatives say the medical teams quickly manage side effects like cytokine release syndrome during phase 1 trials. Many emphasize having a translator ready because consent forms for early-stage studies are frequently in Hebrew.